Cilengitide
Specialist research
Late stageIt was developed as an investigational anticancer agent, principally in glioblastoma.
Substantial controlled clinical research or late stage development has been identified; this is not a product authorisation claim.
What is Cilengitide?
Cilengitide is a cyclic RGD containing pentapeptide integrin inhibitor developed as an investigational anticancer agent and used in glioblastoma and tumour biology research; the catalogue entry denotes the research grade cyclic peptide.
Which research context has Cilengitide been associated with?
Cilengitide is associated with specialist anticancer research as a cyclic RGD pentapeptide integrin inhibitor, predominantly investigated in glioblastoma models and clinical trials assessing tumour integrin signalling and angiogenesis related endpoints.
What documentation is available for Cilengitide?
Cilengitide: Batch documents are not yet linked on this site. For this cyclic RGD pentapeptide integrin inhibitor the checklist comprises batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence or cyclisation confirmation; analytical HPLC/UPLC chromatogram with method and purity specification; peptide content, counterion and residual solvent/water details; and assay/potency documentation. No batch documentation is shown as available until the record for that specific item is linked and reviewed.
What determines the storage conditions for Cilengitide?
Cilengitide: Storage depends on the documented supplied presentation; as a cyclic RGD pentapeptide verify dry/lyophilised versus solution supply, counterion and concentration, solvent or buffer choice, pH sensitivity, container closure compatibility and cyclic conformation stability including susceptibility to oxidation or ring opening. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.